

---

# Contents

## 1 Introduction –

### Positron Emission Tomography: Past and Present 1

1.1 Survey . . . . .	1
Physical and Biochemical Fundamentals . . . . .	2
PET in National and International Medical Care Systems . . . . .	2
1.2 Technological Variants and Developments . . . . .	4
Coincidence PET vs. Dedicated PET . . . . .	4
Differentiated PET Evaluation . . . . .	4
Radiotherapeutic Tools . . . . .	5
PET/CT – a New Key Technology . . . . .	5
Influence of PET/CT on PET . . . . .	5
Studies Dealing with the Cost Efficiency of PET Alone . . . . .	6
PET/CT or Comparison of Co-Registered Findings? . . . . .	6
“Standard” (CARE)-CT and PET/CT . . . . .	6
PET/MRI? . . . . .	6
American Joint Committee on Cancer . . . . .	7
PET Screening in Japan and Taiwan . . . . .	7
1.3 Increased FDG Uptake Due to Physiological and Technical Factors . . . . .	7
1.4 References . . . . .	8

## 2 Fundamentals

### THOMAS BEYER . . . . . 11

2.1 Preface . . . . .	11
Positron Emission Tomography (PET) . . . . .	11
Radioisotopes and PET Tracers . . . . .	12
Coincidence Measurement and Quantification . . . . .	13
PET Measurement Results and Reconstruction . . . . .	14
PET Scanners and Scintillation Detectors . . . . .	16
2.2 Combined PET/CT . . . . .	18
Retrospective Image Fusion . . . . .	18
The PET/CT Prototype . . . . .	18
CT-Based Attenuation Correction . . . . .	20
Commercialization of PET/CT . . . . .	21
New Technical Developments in PET/CT . . . . .	23
PET/CT Acquisition Protocols . . . . .	29
Sources of Errors and Optimization Options . . . . .	30
Radiation Protection Aspects . . . . .	37
2.3 Conclusion . . . . .	40
2.4 References . . . . .	40

## 3 Pneumology . . . . . 43

3.1 Bronchial Carcinoma (BC) . . . . .	43
3.2 Significance of FDG-PET in Diagnostic and Therapeutic Management . . . . .	44
Critical Evaluation of Diagnosis Management . . . . .	45
3.3 Guidelines for <sup>18</sup> F-FDG-PET Indications . . . . .	45
3.4 Technical and Biochemical Factors . . . . .	46
Is Coincidence PET Equivalent to Full-Ring PET? . . . . .	46
PET as Metabolism and Proliferation Marker . . . . .	46
Innovative Radiopharmacy . . . . .	46
3.5 Special PET Indications . . . . .	47
False-Negative PET . . . . .	47
False-Positive PET . . . . .	47
How Useful Is Integrated PET/CT? . . . . .	48
3.6 SCLC (Small-Cell Lung Cancer) . . . . .	48
3.7 Pleural Processes . . . . .	48
Malignant Pleural Tumours (Mesothelioma) . . . . .	49
Imaging Methods . . . . .	49
3.8 Case Studies . . . . .	50
Patient 1 Scar Carcinoma of the Lung . . . . .	50
Patient 2 Pneumonia . . . . .	52
Patient 3 Lymph Node Metastases of a Squamous Cell Carcinoma . . . . .	54
Patient 4 Metastasized Bronchial Carcinoma . . . . .	56
Patient 5 Round Focus in the Lung . . . . .	58
Patient 6 Metastasized Bronchial Carcinoma . . . . .	60
Patient 7 Metastasized Adenocarcinoma in the Left Lower Lobe of the Lung . . . . .	61
Patient 8 Downstaging of a Squamous Cell Carcinoma of the Lung . . . . .	62
Patient 9 Preoperative Staging of a Bronchial Carcinoma . . . . .	64
Patient 10 Pleural Carcinosis after Pneumectomy . . . . .	66
Patient 11 Recurrence of a Brain Metastasis . . . . .	69
Patient 12 Pleural Mesothelioma . . . . .	71
Patient 13 Prevention of Non-Curative Thoracic Surgery . . . . .	73
Patient 14 Upstaging of a Bronchial Carcinoma . . . . .	76
Patient 15 Bilateral Metastases of an NSCLC in the Suprarenal Glands . . . . .	79
3.9 References . . . . .	82

---

<b>4 Gastroenterology</b> . . . . .	<b>85</b>	Patient 7 Hepatocellular Carcinoma with Multiple Metastases . . . . .	114
<b>4.1 Introduction</b> . . . . .	<b>86</b>	Patient 8 Gastric Carcinoma . . . . .	117
Molecular Strategy . . . . .	87	Patient 9 Leiomyoma of the Stomach . . . . .	118
Metabolic Influencing Factors . . . . .	88	Patient 10 Follow-Up of an Adenocarcinoma of the Stomach . . . . .	121
PET Screening? . . . . .	88	Patient 11 Staging of an Adenocarcinoma of the Stomach . . . . .	123
Incidentally Detected Lesions (IDL) . . . . .	88	Patient 12 Staging of a Carcinoma of the Corpus of the Stomach . . . . .	124
<b>4.2 Oesophageal Carcinoma</b> . . . . .	<b>88</b>	Patient 13 Lymph Node Metastasis from Gastric Carcinoma . . . . .	126
PET in Diagnosis Management of Oesophageal Carcinoma . . . . .	88	Patient 14 Extended Metastatic Spread to the Liver from Adenocarcinoma of the Stomach . . . . .	128
<b>4.3 Gastric Carcinoma</b> . . . . .	<b>90</b>	Patient 15 Caecum Carcinoma . . . . .	130
MALT Lymphomas . . . . .	90	Patient 16 Carcinoma of the Colon Ascendens . . . . .	132
<b>4.4 Colorectal Carcinomas</b> . . . . .	<b>90</b>	Patient 17 T1 Carcinoma of the Colon . . . . .	134
Treatment . . . . .	91	Patient 18 Adenocarcinoma of the Sigmoid Colon . . . . .	136
Status of PET . . . . .	91	Patient 19 Liver Metastasis of a Colon Carcinoma . . . . .	138
PET/CT as the Optimum . . . . .	93	Patient 20 Lymphoma Conglomerate Following Colon Carcinoma . . . . .	140
PET Indications . . . . .	93	Patient 21 Lung Metastasis Following Colon Carcinoma . . . . .	142
Limitations of PET . . . . .	94	Patient 22 Pulmonary, Hepatic and Lymphogenic Metastatic Spread Following Sigmoid Carcinoma . . . . .	144
Artefacts . . . . .	94	Patient 23 Metastasized Sigmoid Carcinoma . . . . .	146
FDG-PET . . . . .	94	Patient 24 Peritoneal Carcinosis and Ascites Following Sigmoid Carcinoma . . . . .	148
Alternative and Adjuvant Markers . . . . .	94	Patient 25 Lung Metastasis Following Sigmoid Carcinoma . . . . .	150
Synopsis . . . . .	95	Patient 26 Liver Metastasis Following Sigmoid Carcinoma . . . . .	153
<b>4.5 Liver and Biliary Tract Carcinomas</b> . . . . .	<b>95</b>	Patient 27 Lymph Node Metastasis Following Sigmoid Carcinoma . . . . .	156
<b>4.6 Gastrointestina Stromal Tumours</b> . . . . .	<b>95</b>	Patient 28 Metastatic Spread to the Liver Following Rectal Carcinoma . . . . .	158
<b>4.7 Pancreas Carcinomas</b> . . . . .	<b>96</b>	Patient 29 Liver and Lung Metastases Following Rectal Carcinoma . . . . .	160
Imaging . . . . .	96	Patient 30 Rectal Carcinoma with Lymph Node Metastases . . . . .	163
Curative Treatment . . . . .	97	Patient 31 Suprarenal and Lung Metastases Following Rectal Carcinoma . . . . .	166
New Gene-Based Treatment Strategies . . . . .	97	Patient 32 Lung and Bone Metastases Following Rectal Carcinoma . . . . .	168
Indications . . . . .	97	Patient 33 Suprarenal Metastasis of a Rectal Carcinoma . . . . .	169
DGN Classes, Consequences . . . . .	97	Patient 34 Restaging of a Rectal Carcinoma . . . . .	172
Impact of SUVs on Survival Time . . . . .	97	Patient 35 Suprarenal and Lung Metastases Associated with Rectal Carcinoma . . . . .	174
False-Negative/-Positive PET Findings . . . . .	97	Patient 36 Restaging of a Rectal Carcinoma . . . . .	176
Pancreas NETs (Neuroendocrine Tumours) . . . . .	98	Patient 37 Local Recurrence and Liver Metastases of a Rectal Carcinoma . . . . .	178
<b>4.8 Neuroendocrine Tumours (NETs) of the Gastrointestinal Tract</b> . . . . .	<b>98</b>	Patient 38 Extended Metastatic Spread of a Mesenterial Conglomerate Tumour . . . . .	181
Carcinoids . . . . .	98	Patient 39 GIST Tumour with Liver Involvement . . . . .	183
Conventional Diagnostics . . . . .	98	Patient 40 Malignoma in the Left Epigastric Region . . . . .	184
NET Spectrum . . . . .	99		
Biochemistry . . . . .	99		
High Secretors . . . . .	99		
Low (Non-)Secretors . . . . .	99		
Limitations of PET . . . . .	99		
<b>4.9 Case Studies</b> . . . . .	<b>100</b>		
Patient 1 Oesophageal Carcinoma . . . . .	100		
Patient 2 Lymph Node Metastasis of an Oesophageal Carcinoma . . . . .	103		
Patient 3 Downstaging of an Oesophageal Carcinoma . . . . .	105		
Patient 4 Carcinoma of the Head of the Pancreas . . . . .	107		
Patient 5 Metastasized Carcinoma of the Head of the Pancreas . . . . .	110		
Patient 6 Carcinoma of the Body of the Pancreas . . . . .	112		

Patient 41	GIST, Metastasis at the Greater Curvature of the Stomach. . . . .	186	Patient 5	Restaging of a Breast Cancer . . . . .	224
Patient 42	Tumour Recurrence with Status Post GIST of the Stomach. . . . .	187	Patient 6	Restaging of a Breast Cancer . . . . .	226
Patient 43	Therapy Response Follow-Up Examination Post GIST Resection. . . . .	189	Patient 7	Confirmation of the Diagnosis “Breast Cancer” . . . . .	228
Patient 44	Therapy Follow-Up in the Case of GIST . . . . .	193	Patient 8	Psammoma . . . . .	230
<b>4.10</b>	<b>References . . . . .</b>	<b>200</b>	Patient 9	Ovarian Cancer . . . . .	232
<b>5</b>	<b>Gynaecology . . . . .</b>	<b>205</b>	Patient 10	Restaging of an Ovarian Cancer . . . . .	234
<b>5.1</b>	<b>Introduction . . . . .</b>	<b>206</b>	Patient 11	Therapy Response of a Metastasized Ovarian Cancer . . . . .	236
	The Importance of Nuclear Medical Methods . . . . .	206	Patient 12	Metastasized Cervical Cancer . . . . .	238
<b>5.2</b>	<b>Breast Cancers . . . . .</b>	<b>206</b>	Patient 13	Bone Metastasis of a Corpus Uteri Cancer . . . . .	240
	Mammography . . . . .	207	Patient 14	Trophoblastic Tumour . . . . .	242
	Tumour Markers . . . . .	208	Patient 15	Malignant Ovarian Cyst . . . . .	244
	CT and MRI . . . . .	208	Patient 16	Peritoneal Carcinosis Due to Ovarian Cancer . . . . .	245
	<sup>18</sup> F-Fluoride . . . . .	209	Patient 17	Metastasized Endometrial Carcinoma . . . . .	248
	SPECT . . . . .	209	Patient 18	Exclusion of Metastatic Spread of an Endometrial Carcinoma . . . . .	250
	Sentinel Node Scintigraphy (SNS) . . . . .	209	Patient 19	Therapy Control in Case of Ovarian Carcinoma . . . . .	252
	Positron Emission Tomography . . . . .	209	Patient 20	Lymph Node and Bone Metastases in Case of Ovarian Carcinoma . . . . .	254
	Preoperative Axillary Staging . . . . .	210	Patient 21	Local Recurrence of Breast Cancer . . . . .	256
	Extra-Axillary Metastases . . . . .	211	Patient 22	Restaging of a Breast Cancer after Chemotherapy . . . . .	259
	Treatment Monitoring . . . . .	211	Patient 23	Restaging of a Breast Cancer after Rise in Tumour Marker Level . . . . .	261
	Potentials and Limitations of PET . . . . .	211	Patient 24	Primary Staging of a Breast Cancer . . . . .	262
	Special Neuro-Oncological Problems/Pitfalls . . . . .	212	Patient 25	Restaging of a Breast Cancer after Reduction in Tumour Marker Level . . . . .	264
	PET Screening? . . . . .	212	Patient 26	Pre-Therapeutic Staging of a Breast Cancer . . . . .	267
	Risk Stratification . . . . .	212	Patient 27	Restaging of a Metastasized Breast Cancer . . . . .	269
	PET/CT . . . . .	212	Patient 28	Detection of Metastases by PET/CT with Negative Conventional Imaging . . . . .	271
	Assessment of the Bone Status . . . . .	212	Patient 29	Therapy Control of a Metastasized Breast Cancer . . . . .	275
	<sup>18</sup> F-Fluoride PET . . . . .	212	Patient 30	Therapy Control of a Metastasized Breast Cancer . . . . .	276
	Diagnostic Imaging of the Breast: Indications . . . . .	212	Patient 31	Evaluation of Radiotherapy Response in Case of Metastasized Breast Cancer . . . . .	279
<b>5.3</b>	<b>Ovarian Cancer . . . . .</b>	<b>213</b>	Patient 32	Restaging of a Breast Cancer . . . . .	283
	Tumour Types . . . . .	213	Patient 33	Restaging of a Breast Cancer Revealing a Fracture Risk in the C6 Vertebral Body . . . . .	285
	Conventional Diagnostics . . . . .	213	Patient 34	Restaging of a Breast Cancer with PET/CT Providing Much More Detailed Information . . . . .	287
	PET . . . . .	213	Patient 35	Pleural Carcinosis in a Patient with Breast Cancer . . . . .	290
<b>5.4</b>	<b>Peritoneal Cancer (PC) . . . . .</b>	<b>215</b>	Patient 36	Lung Metastases of a Breast Cancer . . . . .	292
<b>5.5</b>	<b>Cervical Cancer . . . . .</b>	<b>215</b>	Patient 37	Bone Metastases of a Breast Cancer . . . . .	294
	PET Diagnostics . . . . .	215	Patient 38	Male Patient with Metastasized Breast Cancer . . . . .	296
<b>5.6</b>	<b>Case Studies . . . . .</b>	<b>216</b>	<b>5.7</b>	<b>References . . . . .</b>	<b>298</b>
Patient 1	Lymph Node Metastasis with Status Post Carcinoma of the Right Breast and Ovarian Carcinoma on Both Sides . . . . .	216			
Patient 2	Inflammatory Breast Cancer . . . . .	218			
Patient 3	Breast Cancer with Osseous Metastases . . . . .	220			
Patient 4	Preoperative Staging of a Breast Cancer . . . . .	222			

<b>6 Urology</b> . . . . .	303	Patient 26 First Diagnosis of a Prostate Carcinoma . . . . .	361
<b>6.1 Introduction</b> . . . . .	303	Patient 27 Response Evaluation of a Prostate Carcinoma . . . . .	362
<b>6.2 Renal Malignancies</b> . . . . .	304	<b>6.9 References</b> . . . . .	363
Introduction . . . . .	304		
Diagnostics . . . . .	304		
<b>6.3 Adrenal Tumours</b> . . . . .	305		
Imaging Diagnostics . . . . .	305		
<b>6.4 Bladder Carcinoma</b> . . . . .	305	<b>7 Head and Neck Region</b> . . . . .	369
Status of PET . . . . .	306	<b>7.1 Head and Neck Tumours</b> . . . . .	369
<b>6.5 Prostate Carcinoma</b> . . . . .	306	<sup>18</sup> F-FDG-PET . . . . .	371
Introduction . . . . .	306	FDG-PET Pitfalls . . . . .	373
Diagnostics . . . . .	306	PET Indications . . . . .	373
Treatment . . . . .	309	<b>7.2 Thyroid Carcinomas</b> . . . . .	374
Status of Individual Imaging Methods . . . . .	309	<sup>18</sup> F-FDG-PET . . . . .	375
<b>6.6 Germ Cell Tumours</b> . . . . .	313	<b>7.3 Case Studies</b> . . . . .	378
Introduction . . . . .	313	Patient 1 CUP Tumour . . . . .	378
PET Study Situation . . . . .	314	Patient 2 Tumour Recurrence of an Atypical Laryngeal Carcinoid . . . . .	380
<b>6.7 Penis Carcinoma</b> . . . . .	315	Patient 3 Restaging of an Oropharyngeal Carcinoma . . . . .	381
<b>6.8 Case Studies</b> . . . . .	316	Patient 4 Hypopharyngeal Carcinoma . . . . .	384
Patient 1 Malignoma of the Base of the Bladder . . . . .	316	Patient 5 Restaging after Multiple Carcinoma . . . . .	386
Patient 2 Malignoma of the Posterior Wall of the Bladder . . . . .	318	Patient 6 Auricle Carcinoma . . . . .	388
Patient 3 Metastasis in the Suprarenal Gland on the Left Side . . . . .	320	Patient 7 Tonsillar and Laryngeal Carcinoma and Carcinoma of the Base of the Tongue . . . . .	390
Patient 4 Metastasis in the Suprarenal Gland on the Right Side . . . . .	322	Patient 8 Recurrence of a Squamous Cell Carcinoma of the Tongue . . . . .	392
Patient 5 Metastasized Renal Cell Carcinoma . . . . .	325	Patient 9 Tonsillar Carcinoma . . . . .	394
Patient 6 Restaging after Chemotherapy . . . . .	327	Patient 10 Restaging of a Small-Cell Carcinoma of the Left Principal Nasal Cavity . . . . .	396
Patient 7 Restaging after Tumour Nephrectomy . . . . .	330	Patient 11 Recurrence of a Vocal Cord Carcinoma . . . . .	400
Patient 8 Recurrence after Tumour Nephrectomy . . . . .	332	Patient 12 Cerebral Metastatic Spread of a Bronchial Carcinoma . . . . .	402
Patient 9 Metastasized Prostate Carcinoma . . . . .	334	Patient 13 Cystadenocarcinoma of the Lacrimal Sac . . . . .	405
Patient 10 Metastasized Prostate Carcinoma . . . . .	336	Patient 14 Alzheimer's Disease . . . . .	406
Patient 11 Restaging of a Prostate Carcinoma . . . . .	338	Patient 15 Oligodendroglioma on the Left Side . . . . .	408
Patient 12 Lymph Node Metastasis of a Prostate Carcinoma . . . . .	340	Patient 16 Low-Malignancy Brain Tumour on the Left Side . . . . .	410
Patient 13 First Diagnosis of a Prostate Carcinoma . . . . .	342	Patient 17 Hypophyseal Metastasis . . . . .	413
Patient 14 Restaging of a Prostate Carcinoma . . . . .	343	<b>7.4 References</b> . . . . .	415
Patient 15 Restaging of a Prostate Carcinoma . . . . .	345		
Patient 16 Therapy Control for Metastasized Prostate Carcinoma . . . . .	347		
Patient 17 Staging of a Prostate Carcinoma . . . . .	349		
Patient 18 Local Recurrence of a Prostate Carcinoma . . . . .	351		
Patient 19 Lymph Node Metastasis of a Prostate Carcinoma . . . . .	352	<b>8 Dermatology</b> . . . . .	419
Patient 20 Lymph Node Metastases of a Prostate Carcinoma . . . . .	353	<b>8.1 Malignant Melanoma (MM)</b> . . . . .	419
Patient 21 First Diagnosis of a Prostate Carcinoma . . . . .	354	Introduction . . . . .	419
Patient 22 Prostatitis . . . . .	355	Significance of PET . . . . .	421
Patient 23 Prostatitis . . . . .	356	Pitfalls . . . . .	421
Patient 24 Prostatitis . . . . .	357	PET Indications . . . . .	421
Patient 25 Restaging of a Prostate Carcinoma . . . . .	359	<b>8.2 Case Studies</b> . . . . .	422
		Patient 1 Malignant Melanoma of the Right Thigh . . . . .	422
		Patient 2 Recurrent Melanoma . . . . .	424

Patient 3	Metastasized Melanoma . . . . .	426		
Patient 4	Choroidal Melanoma . . . . .	427		
Patient 5	Metastasized Amelanotic Melanoma . . . . .	428		
8.3	References . . . . .	433		
<b>9</b>	<b>Lymphomas</b> . . . . .	435		
9.1	Introduction . . . . .	435		
9.2	Diagnosis . . . . .	436		
	Imaging Methods . . . . .	436		
	FDG-PET . . . . .	437		
	Response Evaluation . . . . .	437		
	Comparison of FDG-PET, <sup>67</sup> Ga and CT. . . . .	438		
	Autologous Stem Cell Therapy. . . . .	438		
	PET/CT Restaging . . . . .	438		
	Artefacts . . . . .	439		
	Other Problems . . . . .	439		
	PET Indications . . . . .	439		
9.3	Case Studies . . . . .	440		
	Patient 1 Follicular Non-Hodgkin's Lymphoma . . . . .	440		
	Patient 2 Metastasized Non-Hodgkin's Lymphoma . . . . .	442		
	Patient 3 B-Cell Lymphoma in the Hypopharynx . . . . .	444		
	Patient 4 B-Cell Lymphoma . . . . .	446		
	Patient 5 Lymphogranulomatosis, Nodular Sclerosis. . . . .	448		
	Patient 6 T-Cell Lymphoma of the Cervical Lymph Tract . . . . .	449		
	Patient 7 B-Cell Lymphoma . . . . .	451		
	Patient 8 Restaging of Hodgkin's Disease . . . . .	454		
	Patient 9 Recurrent Hodgkin's Lymphomas . . . . .	459		
	Patient 10 Chronic Lymphatic Leukaemia . . . . .	461		
	Patient 11 Restaging of the Multiple Myeloma . . . . .	461		
9.4	References . . . . .	463		
<b>10</b>	<b>Oncological Orthopaedics</b> . . . . .	465		
10.1	Introduction . . . . .	465		
10.2	Significance of PET . . . . .	465		
	PET Tracers . . . . .	466		
	PET Indications . . . . .	466		
10.3	Case Studies . . . . .	467		
	Patient 1 Sweat Gland Carcinoma . . . . .	467		
	Patient 2 Haemangioendothelioma . . . . .	470		
	Patient 3 Chondrosarcoma . . . . .	473		
	Patient 4 Medullary Osteosarcoma . . . . .	476		
	Patient 5 Clear Cell Sarcoma . . . . .	478		
	Patient 6 Rhabdomyosarcoma . . . . .	480		
	Patient 7 Rhabdomyosarcoma of the Left Thigh . . . . .	482		
	Patient 8 Embryonal Rhabdomyosarcoma . . . . .	484		
10.4	References . . . . .	486		
<b>11</b>	<b>Paediatric Oncology</b> . . . . .	487		
11.1	Introduction . . . . .	487		
	Changes in the Range of Clinical Indications . . . . .	488		
11.2	Lymphomas in Childhood . . . . .	488		
	Staging, Restaging, Prognosis and Therapy Control . . . . .	488		
11.3	Oncological Orthopaedics in Childhood . . . . .	488		
11.4	Neuroblastomas . . . . .	488		
11.5	Malignant Melanomas . . . . .	488		
11.6	Nesidioblastosis (Congenital Hyperinsulinism) . . . . .	489		
11.7	Case Studies . . . . .	490		
	Patient 1 Status Post Osteogenous Sarcoma . . . . .	490		
	Patient 2 Status Post Mastitis . . . . .	491		
	Patient 3 Embryonal Rhabdomyosarcoma . . . . .	492		
	Patient 4 Focal Congenital Hyperinsulinism . . . . .	494		
	Patient 5 Focal Congenital Hyperinsulinism . . . . .	496		
	Patient 6 Focal Congenital Hyperinsulinism . . . . .	498		
	Patient 7 Diffuse Congenital Hyperinsulinism . . . . .	500		
	Patient 8 Focal Congenital Hyperinsulinism . . . . .	502		
	Patient 9 Focal Congenital Hyperinsulinism . . . . .	504		
	Patient 10 Focal Congenital Hyperinsulinism . . . . .	506		
	Patient 11 Langerhans Cell Histiocytosis . . . . .	508		
	Patient 12 Langerhans Cell Histiocytosis, Staging and Restaging . . . . .	510		
11.8	References . . . . .	514		
<b>12</b>	<b>CUP Tumours</b> . . . . .	515		
	(Cancer of Unknown Primary)			
12.1	Introduction . . . . .	515		
12.2	Significance of PET . . . . .	516		
	Cancer of Unknown Primary: Indication for PET/CT? . . . . .	516		
	Studies Available . . . . .	516		
	Artefacts, Pitfalls and Metabolic Heterogeneity . . . . .	516		
12.3	Case Studies . . . . .	517		
	Patient 1 Carcinoma of the Base of the Tongue . . . . .	517		
	Patient 2 Carcinoma of the Base of the Tongue . . . . .	518		
	Patient 3 Oropharyngeal Carcinoma . . . . .	520		
	Patient 4 Cholangiocarcinoma . . . . .	523		
	Patient 5 Pancreatic Carcinoma . . . . .	526		
	Patient 6 Carcinoma of the Head of the Pancreas . . . . .	528		
	Patient 7 Mamma Carcinoma . . . . .	530		
	Patient 8 CUP Tumour . . . . .	533		
	Patient 9 Mamma Carcinoma . . . . .	536		
	Patient 10 Carcinoma of the Base of the Tongue . . . . .	538		
	Patient 11 Bronchial Carcinoma . . . . .	540		
	Patient 12 Bronchial Carcinoma . . . . .	542		
12.4	References . . . . .	544		

<b>13 Pitfalls</b> . . . . .	545	<b>14 Radiotherapeutic Aspects</b> . . . . .	625
13.1 Testicular Carcinoma and Other Primary Tumours . . . . .	546	14.1 Introduction . . . . .	625
Universal Organ Spectrum of SPT . . . . .	546	14.2 PET-Assisted Radiotherapy Planning . . . . .	625
13.2 Physiological Accumulation of FDG . . . . .	547	14.3 Advantages of PET/CT Integration . . . . .	626
13.3 False Positive FDG Accumulations in the Oncological Sense . . . . .	547	14.4 Fundamentals Governing the Use of PET/CT Data for Radiotherapy – Bits and Bytes and DICOM . . . . .	626
13.4 Artefacts Due to Technical Factors . . . . .	547	14.5 Case Studies . . . . .	630
13.5 False Negative PET Findings . . . . .	547	Patient 1 Prostate Cancer . . . . .	630
13.6 Case Studies Secondary Tumours . . . . .	548	Patient 2 Oropharyngeal Cancer . . . . .	632
Patient 1 Inflammatory Carcinoma of the Breast and Papillary Carcinoma of the Inner Genital Tract . . . . .	548	Patient 3 Breast Cancer . . . . .	634
Patient 2 Carcinoma in Situ with Osteoplastic Metastases 10 years later . . . . .	551	Patient 4 Prostate Cancer . . . . .	636
Patient 3 Recurrence of a Sigmoid Carcinoma, Compression of the Left Ureter . . . . .	554	Patient 5 Squamous Cell Carcinoma of the Oral Cavity . . . . .	638
Patient 4 Cervical Carcinoma and Rectal Carcinoma . . . . .	556	Patient 6 Bronchial Cancer . . . . .	640
Patient 5 Mamma Carcinoma and Colon Carcinoma . . . . .	558	14.6 References . . . . .	643
Patient 6 Mamma Carcinoma and Sigmoid Carcinoma . . . . .	560		
Patient 7 Thymoma . . . . .	561	<b>15 Nuclear Cardiology</b> . . . . .	645
Patient 8 Prostate Carcinoma and Colon Carcinoma . . . . .	564	– the Situation in Europe	
Patient 9 Renal Cell and Prostate Carcinoma . . . . .	566	15.1 Introduction . . . . .	645
Patient 10 Prostate Carcinoma and Colon Carcinoma . . . . .	568	Development of Nuclear Cardiology and the Present State . . . . .	645
Patient 11 Carcinoma in Situ of the Rectum and Bronchial Carcinoma . . . . .	570	Molecular Cardiac Imaging . . . . .	647
Patient 12 Non-Hodgkin's Lymphoma and Bronchial Carcinoma . . . . .	574	Fusion Imaging . . . . .	649
Patient 13 Mamma Carcinoma and Bronchial Carcinoma . . . . .	577	SPECT and SPECT/CT . . . . .	650
Patient 14 Coecum, Bronchial and Renal Carcinoma . . . . .	579	MRI and PET/MRI . . . . .	652
Patient 15 Mamma, Cervical and Rectal Carcinoma . . . . .	583	15.2 Cardiac PET/CT . . . . .	652
Patient 16 Parotid and Colon Carcinoma . . . . .	586	Coronary Sclerosis . . . . .	652
13.7 Case Studies		Diabetes Mellitus and Coronary Sclerosis . . . . .	654
Physiologically Increased Uptake . . . . .	589	Plaque Imaging . . . . .	655
Patient 17–21 . . . . .	589	Perfusion . . . . .	656
13.8 Case Studies		Vitality . . . . .	657
Non-Oncological Increased Uptake of Inflammatory Genesis . . . . .	593	Radiation Exposure and Contrast Medium Safety . . . . .	657
Patient 22–31 . . . . .	593	Artefacts . . . . .	658
13.9 Case Studies		Invasive Diagnostics, Treatment and Treatment Monitoring . . . . .	658
Artefacts . . . . .	611	Prevention . . . . .	661
Patient 32–39 . . . . .	611	Remarks on the Catalogue for Further Training for the Specialization in Nuclear Medicine . . . . .	661
13.10 References . . . . .	622	15.3 Case Studies . . . . .	663
		Patient 1 Mild CHD . . . . .	663
		Patient 2 Status Post Revascularization . . . . .	666
		Patient 3 Status Post Anterior Infarction and Sextuple Bypass . . . . .	668
		Patient 4 Surprise Finding of Stem Stenosis . . . . .	672
		15.4 Reference . . . . .	676

<b>16 Cardiac PET and PET/CT</b> . . . . .	687	<b>16.4 Vascular Inflammation and Atherosclerosis</b> . .	709
– the Situation in the USA		16.4.1 Large Vessel Vasculitis . . . . .	709
<b>16.1 Introduction</b> . . . . .	687	16.4.2 Atherosclerosis and Plaque Imaging	711
<b>16.2 Coronary Artery Disease</b> . . . . .	687	<b>16.5 Future Developments</b> . . . . .	714
Imaging with PET . . . . .	688	<b>16.6 References</b> . . . . .	714
Accuracy of PET and PET/CT Stress-Rest			
Myocardial Perfusion Imaging . . . . .	693		
Advantages of Myocardial Perfusion Imaging			
with PET . . . . .	696		
Hybrid PET/CT Myocardial Perfusion Imaging			
in Coronary Artery Disease . . . . .	697		
<b>16.3 Myocardial Viability</b> . . . . .	698		
Concepts and Pathophysiology . . . . .	699		
Assessment of Myocardial Viability . . . . .	699		
Imaging of Myocardial Perfusion			
and Metabolism . . . . .	701		
Clinical Implications of			
Perfusion Metabolism Imaging . . . . .	705		
PET/CT vs. Stand-Alone PET. . . . .	707		
Clinical Indications of			
Perfusion Metabolism Imaging . . . . .	708		
		<b>17 Future Trends: Molecular PET</b> . . . . .	721
		<b>17.1 Technical Potential and</b>	
		<b>Software Optimization</b> . . . . .	721
		<b>17.2 Molecular PET</b> . . . . .	722
		Tumour Vitality and	
		Glucose Transporters (GLUT) . . . . .	722
		Therapeutic and Diagnostic Potential . . . . .	722
		<b>17.3 Final Remark</b> . . . . .	723
		<b>17.4 References</b> . . . . .	724
		<b>Subject Index</b> . . . . .	727